DRL to market and distribute Amgen’s Repatha, Kyprolis and BLINCYTO in India upon approval
Dr Reddy’s Laboratories (DRL) has entered into a strategic collaboration with Amgen, a leading independent biotechnology companies, to market and distribute three Amgen medicines in India in the areas of oncology and cardiology. Under the terms of the collaboration, DRL shall perform a full range of regulatory and commercial services to seek approval and launch Kyprolis (carfilzomib), BLINCYTO (blinatumomab) and Repatha (evolocumab) in India.
The collaboration leverages the capabilities of both companies, combining three of Amgen’s innovative therapies with DRL’s deep understanding of patient and physician needs in India.
Alok Sonig, Executive Vice President and Head of India Business & Global Business Development, DRL stated, “We are excited about our strategic collaboration with Amgen and look forward to making their innovative medicines accessible to Indian patients. Addressing significant unmet needs of patients in oncology and cardiovascular are key areas in India and, therefore, a priority for us at DRL’s.”
“We are pleased to be joining forces with DRL in order to make Amgen’s innovative medicines available to patients in India,” said Penny Wan, Amgen Vice President and General Manager, Japan Asia Pacific Region.
Kyprolis, approved by the US Food and Drug Administration in July 2015, in combination with lenalidomide and dexamethasone, is used for the treatment of patients with relapsed multiple myeloma who have received one to three prior lines of therapy. BLINCYTO is an example of immunotherapy, a treatment that uses certain parts of a person’s immune system to fight diseases such as cancer. In July, this year, the European Commission (EC) granted marketing authorisation for Repatha, the first proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor to be approved in the world, for the treatment of patients with uncontrolled cholesterol despite taking maximum doses of statins or who cannot take statins, who require additional intensive low-density lipoprotein cholesterol (LDL-C) reduction.